ΞMENU

ONCOLOGY

To support drug discovery projects in oncology, we perform high-content analysis either in cellular models of human tumors in 2D or 3D, or directly in tumor tissues and blood samples. Combining a panel of validated assays for immediate performance and more than 10-year experience in assay development, we assist pharmaceutical companies and academic researchers in the discovery of new cancer drug targets, the identification of new anticancer compounds, and the quantitative analysis of novel cancer biomarkers.

Cancer
Assays

3D Tumor
Spheroids

Cancer biomarkers
analysis in blood

Cancer biomarkers<br/>analysis in tissues

Cancer biomarkers
analysis in tissues

Oncology readouts

ONCOLOGY READOUTS

CELL PHYSIOLOGY (PROLIFERATION & CELL CYCLE/MIGRATION, ADHESION & DIFFERENTIATION/ANGIOGENESIS)

Clonogenicity	Multiple cellular models	PF 10.4
Cell cycle	Multiple cellular models	PF 3.8
Cell proliferation	Multiple cellular models	PF 3.9
Migration	Multiple cellular models	PF 3.14
Invasion (3D)	Multiple cellular models	PF 3.15
Angiogenesis (endothelial/microendothelial tube formation)	HUVECs/HDMECs Cells/R/6A cells	PF 10.8
c-myc expression	Multiple cellular models	PF 10.25
Pan keratin expression	Multiple cellular models	PF 10.13

CELL STRESS AND METABOLISM

Intracellular reactive oxygen species	Multiple cellular models	PF 3.11
y-secretase activity	Established HeLa cell clone	PF 3.13
Lipid peroxidation	Multiple cellular models	PF 3.18
Glutathione (GSH), intracellular GSH content	Multiple cellular models	PF 3.28
Hypoxia analysis/quantification	Multiple cellular models	PF 3.20
Heme Oxygenase 1 expression	Multiple cellular models	PF 3.25
MnSOD induction	Multiple cellular models	PF 10.43
Protein-protein interaction	Multiple cellular models	PF 10.28
cAMP quantification	Multiple cellular models	PF 3.27
Calcium signaling	Multiple cellular models	PF 3.33
FLIP expression	Multiple cellular models	PF 10.27
Line-1 expression	Multiple cellular models	PF 10.26
c-myc expression	Multiple cellular models	PF 10.25
Src expression	Multiple cellular models	PF 10.24
FRS phosphorylation	Multiple cellular models	PF 10.23
PLCy phosphorylation	Multiple cellular models	PF 10.21
Cytochrome c release	Multiple cellular models	PF 10.5
Fas expression/phosphorylation	Multiple cellular models	PF 10.16
Protein synthesis quantification	Multiple cellular models	PF 10.46
Lipid, intracellular accumulation: neutral lipids	Multiple cellular models	PF 3.29
Lipid, intracellular accumulation: phospholipids	Multiple cellular models	PF 3.30
NAD(P)H / FAD	Multiple cellular models	PF 3.31

DNA DAMAGE, CELL DEATH AND APOPTOSIS

NEW ! Immune cell killing	RKO Cell line	PF 10.47
Caspase 3/7 activity	Multiple established cell clones	PF 3.1
Caspase 3/7 activation	Multiple cellular models	PF 3.2
Mitochondrial membrane potential	Multiple cellular models	PF 3.3
Cytolysis	Multiple cellular models	PF 3.4
Calpain activity	Multiple established cell clones	PF 3.12
Autophagy (LC3B)	Multiple cellular models	PF 3.17
DNA oxidation	Multiple cellular models	PF 10.6
Histone H3 acetylation (Lys9)	Multiple cellular models	PF 10.19
Micronuclei	Blood	PF 10.22
Caspase 9 activation	Multiple cellular models	PF 10.45
PARP (cleaved)	Multiple cellular models	PF 10.44
dnMT1 expression	Multiple cellular models	PF 10.37
PCNA expression	Multiple cellular models	PF 10.34
Bad expression	Multiple cellular models	PF 10.33
Bcl2 expression	Multiple cellular models	PF 10.32
Bax activation	Multiple cellular models	PF 10.31
Mcl1 expression	Multiple cellular models	PF 10.30
Noxa	Multiple cellular models	PF 10.29
Cytochrome c release	Multiple cellular models	PF 10.5
Apoptosis (Annexin V) quantification	Multiple cellular models	PF 10.2
Caspase 8 activity	Multiple cellular models	PF 10.3

RECEPTOR PHARMACOLOGY AND SIGNALING PATHWAYS

Glucocorticoid receptor subcellular translocation	AtT20 primary rat nuclear translocation pituitary cells	PF 3.26
Androgen receptor nuclear translocation	LnCaP cell line	PF 10.1
Prostate Specific Antigen (PSA) expression	LnCap cell line	PF 10.15
p21 quantification	Multiple cellular models	PF 10.18
p38 phosphorylation	Multiple cellular models	PF 10.20
p53 expression level/activation	Multiple cellular models	PF 10.17
NF kB activation	Multiple cellular models	PF 3.23
Ras expression	Multiple cellular models	PF 10.14
MEK phosphorylation	Multiple cellular models	PF 10.36
ERK activation (pERK1/2)	Multiple cellular models	PF 3.27
cAMP quantification	Multiple cellular models	PF 3.40
Calcium homeostasis	Multiple cellular models	PF 3.33
STAT1 translocation	Multiple cellular models	PF 3.36
STAT2 translocation	Multiple cellular models	PF 3.35
STAT3 translocation	Multiple cellular models	PF 3.37
STAT5 phosphorylation	Multiple cellular models	PF 10.35
STAT6 phosphorylation	Multiple cellular models	PF 3.34
Poly-Ubiquitin detection	Multiple cellular models	PF 3.28
S6 RP expression/phosphorylation	Multiple cellular models	PF 10.42
c-Jun phosphorylation	Multiple cellular models	PF 10.41
mTOR phosphorylation	Multiple cellular models	PF 10.40
CREB phosphorylation	Multiple cellular models	PF 3.27
PKCα activation	Multiple cellular models	PF 10.39
Rb phosphorylation	Multiple cellular models	PF 10.38
AKT phosphorylation	Multiple cellular models	PF 10.7
FLIP expression	HCT-116 cell line	PF 10.27
Src expression	Multiple cellular models	PF 10.24
FRS2 phosphorylation	MRT4 cell line	PF 10.23
PLCy phosphorylation	Multiple cellular models	PF 10.21
Fas expression/phosphorylation	Multiple cellular models	PF 10.16
Prostate Specific Antigen (PSA) expression	Multiple cellular models	PF 10.15
VHL expression	ACHN cell line	PF 10.10
P130 CAS expression/phosphorylation	ACHN cell line	PF 10.11
FAK expression	ACHN cell line	PF 10.12

ONCOLOGY

ONCOLOGY READOUTS

Fluofarma

WORLDWIDE PRESENCE